- ESAs in theory and practice in an oncology patient2022 | Faculty of Medicine in Pilsen
- Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact2010 | First Faculty of Medicine
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial2023 | First Faculty of Medicine
- 2.3.1. Erythropoetin2012 | First Faculty of Medicine
- Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact2010 | Publication without faculty affiliation
- Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies2011 | Publication without faculty affiliation
- Hemoglobin level in patients with chronic kidney disease and its impact on mortality2011 | First Faculty of Medicine
- When to use ESA and iron substitution in a cancer patient2021 | Faculty of Medicine in Pilsen
- Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents2016 | First Faculty of Medicine
- Pathogenesis and treatment of anaemia in cancer2013 | First Faculty of Medicine
- Treatment strategies for myelodysplastic syndrome in 20212021 | Faculty of Medicine in Hradec Králové
- Significance and risks of growth factors of erythropoiesis2021 | Faculty of Medicine in Pilsen
- Chronic renal failure and malignant tumors2015 | First Faculty of Medicine
- Anaemia in chronic heart failure2010 | First Faculty of Medicine
- A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease2009 | Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis2019 | Faculty of Medicine in Pilsen
- Overview of erythropoietic agents.2011 | First Faculty of Medicine
- Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial2009 | First Faculty of Medicine
- Anemia in patients with kidney disease and possibilities of management2011 | First Faculty of Medicine
- Novel treatment options for anaemia in patients with chronic kidney disease +12018 | First Faculty of Medicine
- New developments in anaemia treatment - erythropoietin versus prolyl hydroxylase inhibitors?2022 | First Faculty of Medicine
- Impact of global economic disparities on practices and outcomes of chronic peritoneal dialysis in children: insights from the International Pediatric Peritoneal Dialysis Network Registry2012 | Second Faculty of Medicine
- Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial2018 | First Faculty of Medicine
- What Is the Quality of Pre-Dialysis Healthcare in the Czech Republic?2012 | Third Faculty of Medicine
- Management of Anemia in Children Receiving Chronic Peritoneal Dialysis2013 | Second Faculty of Medicine
- Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide2008 | Third Faculty of Medicine
- Prevalence and predictors of the sub-target Hb level in children on dialysis2012 | Second Faculty of Medicine
- Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial2017 | Second Faculty of Medicine